Why the study?
Does aspirin or coumadin reduce reocclusion and recurrent ischemia in patients after successful thrombolysis compared to placebo?
Population
300 patients treated with intravenous thrombolytic therapy followed by intravenous heparin with a patent…
Comparison
Aspirin 325 mg daily or Coumadin for 3 months. vs Placebo with discontinuation of heparin.
Design
RCT, Randomized to three arms, Placebo-controlled
Follow-up
3 months
Authors
Loading...
Reocclusion prevention not achieved with aspirin or coumadin after successful thrombolysis; extends evidence that clinical benefits may occur independently of angiographic findings.
Does aspirin or coumadin reduce reocclusion and recurrent ischemia in patients after successful thrombolysis compared to placebo?
While neither aspirin nor coumadin significantly reduced angiographic reocclusion rates at 3 months compared to placebo, aspirin significantly reduced reinfarction and revascularization rates and improved event-free survival.
Meijer et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: